CrystalSDenlingerMD

Oncology • Plymouth Meeting, PA

Gastrointestinal Cancer, Hematologic Oncology

Senior Vice President, Chief Scientific Officer, National Comprehensive Cancer Network

Join to view full profile

Dr. Denlinger is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Denlinger's full profile

Already have an account?

Office
3025 Chemical Rd
Suite 100
Plymouth Meeting, PA 19462
Phone+1 267-622-6654

Summary

Provides oversight to NCCN’s Oncology Research Program and select Compendia products. Participates in NCCN policy and global initiatives. Practicing clinician with part-time voluntary faculty appointment at Fox Chase Cancer Center.

Education & Training

Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2001 - 2004
Rutgers New Jersey Medical SchoolClass of 2001

Certifications & Licensure

PA State Medical License 2004 - 2024
NY State Medical License 2002 - 2004
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Fellow American College of Physicians

Clinical Trials

Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment Start of enrollment: 2008 Jul 01
Completed
Phase 1
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Completed
Phase 3
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer Start of enrollment: 2011 Apr 27
Completed
Phase 2
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2010 Mar 01
Terminated
Not Applicable
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors Start of enrollment: 2011 Oct 01
Completed
Phase 1
Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care Start of enrollment: 2013 Jan 01
Completed
Not Applicable
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Start of enrollment: 2012 Dec 01
Completed
Phase 2
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Start of enrollment: 2013 Jan 01
Terminated
Phase 2
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer Start of enrollment: 2014 Jan 01
Completed
Phase 1
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Start of enrollment: 2016 May 19
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

22 citations
A Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab with or Without Bevacizumab as Frontline Therapy for Metastatic Colorectal Cancer. A Fox Chase Extramural ...
Efrat Dotan, Neal J. Meropol, Barbara Burtness, Crystal S. Denlinger, James C. Lee
Journal of Gastrointestinal Cancer. 2012-02-01
68 citations
NCCN guidelines® insights survivorship, version 1.2016 featured updates to the NCCN Guidelines
Crystal S. Denlinger, Jennifer A. Ligibel, Madhuri Are, K. Scott Baker, Gregory A. Broderick
Journal of the National Comprehensive Cancer Network. 2016-06-01
364 citations
American College of Sports Medicine Roundtable Report on Physical Activity, Sedentary Behavior, and Cancer Prevention and Control.
Alpa V. Patel, Christine M. Friedenreich, Steven C. Moore, Sandra C. Hayes, Julie K. Silver
Medicine and Science in Sports and Exercise. 2019-11-01

Journal Articles

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S Hong, Marwan G Fakih, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Adrian Sacher, Crystal S Denlinger, John C Krauss, Andrew L Coveler, Suresh S Rama..., The New England Journal of Medicine

Lectures

Impact of Health Disparities on Cancer Survivorship
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020

Authored Content

Cardiovascular Toxicity in Cancer Survivors: Current Guidelines and Future DirectionsJune 2018

Press Mentions

NCCN’s Cancer Care Guidelines Expanded to Include More Hereditary RisksNovember 12th, 2024
NCCN Genetic Testing Guidelines Expanded for High-Risk Cancer AssessmentNovember 8th, 2024
NCCN Guidelines Have Expanded to Meet Growing Understanding of Hereditary RiskNovember 7th, 2024
Join now to see all

Grant Support

NCCN Foundation Young Investigator AwardNCCN Foundation2012–2014

Committees

Chair, NCCN Survivorship Guidelines Panel 2012 - Present
Member, Chemotherapy subcommittee, NCCN Esophagogastric Cancers Guidelines Panel 2009 - Present
Member, NCI Esophagogastric Task Force 2012 - 2013